Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SEHK: 6990)
Salud · Biotecnología · CN
448,00 HK$
-2,18 % hoy · -3,7 % 1 año
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SEHK: 6990) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 13,65 mil M $ y tiene 2300 empleados.
En los últimos doce meses la acción ha bajado un 3,7 % y ha cotizado entre 339,60 y 562,50.
Tweenvest puntúa a Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. en cuatro factores: calidad 55/100, valor 5/100. Su punto más fuerte es calidad.
Evolución de la cotización de 6990
Cifras clave
- Capitalización
- 13,65 mil M $
- Ingresos (últ. 12 m)
- 307,06 M $
- PER
- 631,17
- BPA
- 0,75
- Rent. por dividendo
- —
- Beta (5 años)
- 0,10
- Máximo 52 semanas
- 562,50 HK$
- Mínimo 52 semanas
- 339,60 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 239,02 M
- Empleados
- 2300
- Próximos resultados
- —
Sobre Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
- ISIN
- CNE1000062J1
- Fundada en
- 2016
- Cotiza desde
- 11 jul 2023
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Exelixis, Inc.NasdaqGS: EXEL | 16,66 mil M $ | 68,29 $ | -0,31 % |
| Neurocrine Biosciences, Inc.NasdaqGS: NBIX | 16,48 mil M $ | 162,86 $ | -1,86 % |
| Swedish Orphan Biovitrum AB (publ)OM: SOBI | 16,28 mil M $ | 472,80 Skr | -1,54 % |
| BridgeBio Pharma, Inc.NasdaqGS: BBIO | 15,20 mil M $ | 78,01 $ | +1,58 % |
| BioMarin Pharmaceutical Inc.NasdaqGS: BMRN | 11,90 mil M $ | 61,43 $ | +4,99 % |
| Halozyme Therapeutics, Inc.NasdaqGS: HALO | 10,92 mil M $ | 95,80 $ | -0,18 % |
| Kymera Therapeutics, Inc.NasdaqGM: KYMR | 10,34 mil M $ | 121,13 $ | -0,32 % |
| Madrigal Pharmaceuticals, Inc.NasdaqGS: MDGL | 9,93 mil M $ | 427,39 $ | +0,51 % |